Manufacturing

Sample preparation tends to be manually labor intensive, but automating this step helps streamline the glycosylation monitoring workflow.

Persistent bottlenecks in biocatalyst development can be alleviated through fully automated enzyme analysis.

Workforce training is crucial for biopharmaceutical manufacturing.

A new focus on speed to market creates challenges for facility design and construction.

Continued process verification for a cleaning validation program begins once the validation study is complete.

Scitara’s Scientific Integration Platform (SIP) establishes a flexible, adaptable framework that facilitates a fully connected laboratory.

Thermo Fisher's Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency.

The MicroEDS BioWaste Treatment System can process between 150 to 500 L of waster per day.

Sanofi’s acquisition of Amunix will grant access to their promising immuno-oncology pipeline.

Amgen and Syngene International have extended their research collaboration to 2026.

Genezen has opened its new process development and analytical lab for viral vector production.

Pfizer invested $68.5 million in a facility in Durham, NC.

FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.

FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.

SKAN’s new Cellana isolator is designed for GMP manufacturing of ATMPs.

Fareva plans to use blow-fill-seal equipment and ApiJect’s prefilled injector technology to create fill/finish capacity in France.

New processes, automation, and digitalization were highlighted in 2021.

Guide addresses challenges of applying GMPs to autologous cell therapy manufacturing.

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.

Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

A new Cytiva FlexFactory platform will be installed at Taiyo Pharma Tech’s site in Osaka, Japan.

Fujifilm’s new cell culture media manufacturing facility in the Netherlands has officially opened.

The additions to Crown Bioscience’s UK facility will increase and expand the company’s current in-vivo offering.

Fujifilm’s center adds local support in Suzhou, China for cell culture media optimization.

Moderna’s agreement with the UK government includes 29 million COVID-19 vaccine doses for delivery in 2022 and 31 million doses for delivery in 2023.

High price tags threaten to block patient access to potentially life-saving cures and treatments.

Bio/pharmaceutical manufacturing harnesses the benefits of digital transformation.

Polpharma implemented digital technologies, including a digital twin of operations.

Isolators move into smaller-volume processes, including cell and gene therapy manufacturing.